Position in MBX
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$0
+$0 QoQ
Shares Held
0
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2024
5 quarters on record
Common Shares in MBX Over Time
Shares Held
Position Value (USD)
Derivatives in MBX
reported options exposure · as of Jun 30, 2026CallValue
$2,075,520
CallShares
37,600
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Jun 30, 2026JANE STREET GROUP, LLC holds $1,372,861,470 across 292 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | BBIO |
BridgeBio Pharma, Inc.
|
2,934,193 | $218,538,693 | |
| 2 | MDGL |
Madrigal Pharmaceuticals, Inc.
|
191,541 | $102,847,939 | |
| 3 | AXSM |
Axsome Therapeutics, Inc.
|
403,995 | $98,885,855 | |
| 4 | TGTX |
Tg Therapeutics, Inc.
|
1,752,646 | $96,290,370 | |
| 5 | EXEL |
Exelixis, Inc.
|
1,402,438 | $76,306,651 | |
| 6 | QURE |
uniQure N.V.
|
1,610,483 | $74,178,846 | |
| 7 | HALO |
Halozyme Therapeutics, Inc.
|
694,684 | $54,372,915 | |
| 8 | TVTX |
Travere Therapeutics, Inc.
|
938,699 | $53,327,489 |
All Filings in MBX
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $2,075,520 | 37,600 | Call | Defined | 2026-08-14 | |
| 2026-03-31 | $597,000 | 20,000 | Call | Defined | 2026-05-12 | |
| 2026-03-31 | $650,730 | 21,800 | Put | Defined | 2026-05-12 | |
| 2025-12-31 | $520,410 | 16,500 | Call | Defined | 2026-02-12 | |
| 2025-12-31 | $2,730,764 | 86,581 | Shares | Defined | 2026-02-12 | |
| 2025-09-30 | $633,500 | 36,200 | Put | Defined | 2025-11-14 | |
| 2024-09-30 | $690,288 | 26,570 | Shares | Defined | 2024-11-15 | |
| No filing history on record for this holder in this stock. | ||||||